On September 20, 2019, the District Court for the District of Delaware endorsed a joint stipulation of the parties to dismiss all claims and counterclaims in the Genentech v. Pfizer BPCIA litigation concerning Pfizer’s ZIRABEV (bevacizumab-bvzr), a biosimilar of AVASTIN. According to the stipulation, the parties entered into a settlement agreement and mutually agreed to voluntary dismissal of the suit.
Although Genentech’s BPCIA litigation against Pfizer was short-lived, with the complaint filed just this past April, Genentech remains locked in litigation against Amgen concerning Amgen’s recently launched bevacizumab biosimilar, MVASI. The Genentech v. Amgen suit has been pending since 2017, and is scheduled for a jury trial in July 2020.
The post Genentech and Pfizer Settle Bevacizumab Biosimilar Litigation appeared first on Big Molecule Watch.